From circadian clocks to non-alcoholic fatty liver disease

References

• Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011 Jul;54(1):344–353.
   PubMedGoogle Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int. 2016 Mar;36(3):317–324.
   PubMed Web of Science ®Google Scholar
• Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017 Oct;67(4):862–873.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci. 2017 Nov 15;131(22):2701–2704.
   PubMed Web of Science ®Google Scholar
• Neuman MG, Cohen LB, Nanau RM. Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 2014 Dec;28(11):607–618.
   PubMed Web of Science ®Google Scholar
• Gong Z, Tas E, Yakar S, et al. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Mol Cell Endocrinol. 2017 Nov 5;455:115–130.
   PubMed Web of Science ®Google Scholar
• Szewczyk-Golec K, Wozniak A, Reiter RJ. Inter-relationships of the chronobiotic, melatonin, with leptin and adiponectin: implications for obesity. J Pineal Res. 2015 Oct;59(3):277–291.
   PubMed Web of Science ®Google Scholar
• Kim TW, Jeong JH, Hong SC. The impact of sleep and circadian disturbance on hormones and metabolism. Int J Endocrinol. 2015;2015:591729.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015 Mar;148(3):547–555.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015 Dec;62(6):1723–1730.
   PubMed Web of Science ®Google Scholar
• Zhu JZ, Zhou QY, Wang YM, et al. Prevalence of fatty liver disease and the economy in China: a systematic review. World J Gastroenterol. 2015 May 14;21(18):5695–5706.
   PubMed Web of Science ®Google Scholar
• Massoud O, Charlton M. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis and hepatocellular carcinoma. Clin Liver Dis. 2018 Feb;22(1):201–211.
   PubMed Web of Science ®Google Scholar
• Lau LHS, Wong SH. Microbiota, obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111–125.
   PubMed Web of Science ®Google Scholar
• Graffy PM, Pickhardt PJ. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br J Radiol. 2016 Jun;89(1062):20151024.
   PubMed Web of Science ®Google Scholar
• Hazlehurst JM, Woods C, Marjot T, et al. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65(8):1096–1108.
   PubMed Web of Science ®Google Scholar
• Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009 Jan-Mar;13(1):9–19.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yin M, Cao X, et al. Pro- and anti-inflammatory effects of high cholesterol diet on aged brain. Aging Dis. 2018 Jun;9(3):374–390.
   PubMed Web of Science ®Google Scholar
• Fournet M, Bonte F, Desmouliere A. Glycation damage: a possible hub for major pathophysiological disorders and aging. Aging Dis. 2018 Oct;9(5):880–900.
   PubMed Web of Science ®Google Scholar
• Hu M, Phan F, Bourron O, et al. Steatosis and NASH in type 2 diabetes. Biochimie. 2017;143:37–41.
   PubMed Web of Science ®Google Scholar
• Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017 May;49(2):197–211.
   PubMed Web of Science ®Google Scholar
• Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018 Feb;68(2):280–295.
   PubMed Web of Science ®Google Scholar
• Arrese M, Cabrera D, Kalergis AM, et al. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci. 2016 May;61(5):1294–1303.
   PubMed Web of Science ®Google Scholar
• Brown SA. A new histone code for clocks? Science. 2011;333(6051):1833–1834.
   PubMed Web of Science ®Google Scholar
• Brown SA, Kowalska E, Dallmann R. (Re) inventing the circadian feedback loop. Dev Cell. 2012;22(3):477–487.
   PubMed Web of Science ®Google Scholar
• Gerber A, Saini C, Curie T, et al. The systemic control of circadian gene expression. Diabetes Obes Metab. 2015 Sep;17(Suppl 1):23–32.
   PubMedGoogle Scholar
• Orozco-Solis R, Sassone-Corsi P. Epigenetic control and the circadian clock: linking metabolism to neuronal responses. Neuroscience. 2014 Apr 4;264:76–87.
   PubMed Web of Science ®Google Scholar
• Canaple L, Rambaud J, Dkhissi-Benyahya O, et al. Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor α defines a novel positive feedback loop in the rodent liver circadian clock. Mol Endocrinol. 2006;20(8):1715–1727.
   PubMedGoogle Scholar
• Sato F, Kohsaka A, Bhawal UK, et al. Potential roles of Dec and Bmal1 genes in interconnecting circadian clock and energy metabolism. Int J Mol Sci. 2018 Mar 8;19(3):781.
   Web of Science ®Google Scholar
• Yamajuku D, Shibata Y, Kitazawa M, et al. Cellular DBP and E4BP4 proteins are critical for determining the period length of the circadian oscillator. FEBS Lett. 2011 Jul 21;585(14):2217–2222.
   PubMed Web of Science ®Google Scholar
• Mazzoccoli G, De Cosmo S, Mazza T. The biological clock: a pivotal hub in non-alcoholic fatty liver disease pathogenesis. Front Physiol. 2018;9:193.
   PubMed Web of Science ®Google Scholar
• Shi D, Chen J, Wang J, et al. Circadian clock genes in the metabolism of non-alcoholic fatty liver disease. Front Physiol. 2019;10:423.
   Web of Science ®Google Scholar
• Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science (New York, NY). 1995 Jul 28;269(5223):543–546.
   Google Scholar
• Moon HS, Dalamaga M, Kim SY, et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013 Jun;34(3):377–412.
   PubMed Web of Science ®Google Scholar
• Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011 Oct;301(4):E567–84.
   PubMed Web of Science ®Google Scholar
• Zhang F, Chen Y, Heiman M, et al. Leptin: structure, function and biology. Vitam Horm. 2005;71:345–372.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Suchard MA, Wong ML, et al. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10434–10439.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism. 2015 Jan;64(1):60–78.
   PubMed Web of Science ®Google Scholar
• Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996 Jul 18;382(6588):250–252.
   PubMed Web of Science ®Google Scholar
• Bodosi B, Gardi J, Hajdu I, et al. Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. Am J Physiol Regul Integr Comp Physiol. 2004 Nov;287(5):R1071–9.
   PubMed Web of Science ®Google Scholar
• Ando H, Kumazaki M, Motosugi Y, et al. Impairment of peripheral circadian clocks precedes metabolic abnormalities in ob/ob mice. Endocrinology. 2011 Apr;152(4):1347–1354.
   PubMed Web of Science ®Google Scholar
• Hwang CS, Mandrup S, MacDougald OA, et al. Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein alpha. Proc Natl Acad Sci U S A. 1996;93(2):873–877.
   PubMed Web of Science ®Google Scholar
• Hollenberg AN, Susulic VS, Madura JP, et al. Functional antagonism between CCAAT/Enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter. J Biol Chem. 1997 Feb 21;272(8):5283–5290.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Aronis KN, Kountouras J, et al. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016 Jan;59(1):30–43.
   PubMed Web of Science ®Google Scholar
• Chang ML, Hsu CM, Tseng JH, et al. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. J Gastroenterol Hepatol. 2015 Feb;30(2):329–336.
   PubMed Web of Science ®Google Scholar
• Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav. 2014 May 10;130:157–169.
   PubMed Web of Science ®Google Scholar
• Volmer R, Ron D. Lipid-dependent regulation of the unfolded protein response. Curr Opin Cell Biol. 2015 Apr;33:67–73.
   PubMed Web of Science ®Google Scholar
• Martinez de Morentin PB, Varela L, Ferno J, et al. Hypothalamic lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2010 Mar;1801(3):350–361.
   PubMed Web of Science ®Google Scholar
• Tahara Y, Shibata S. Circadian rhythms of liver physiology and disease: experimental and clinical evidence. Nat Clin Pract Gastroenterol Hepatol. 2016 Apr;13(4):217–226.
   Google Scholar
• Challet E. Circadian aspects of adipokine regulation in rodents. Best Pract Res Clin Endocrinol Metab. 2017 Dec;31(6):573–582.
   PubMed Web of Science ®Google Scholar
• Zhang R, Lahens NF, Ballance HI, et al. A circadian gene expression atlas in mammals: implications for biology and medicine. Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16219–16224.
   PubMed Web of Science ®Google Scholar
• Agil A, El-Hammadi M, Jimenez-Aranda A, et al. Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats. J Pineal Res. 2015 Aug;59(1):70–79.
   PubMed Web of Science ®Google Scholar
• Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15(3):434–443.
   PubMed Web of Science ®Google Scholar
• Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009 Jan;41(1):89–94.
   PubMed Web of Science ®Google Scholar
• Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009 Jan;41(1):77–81.
   PubMed Web of Science ®Google Scholar
• Lane JM, Chang AM, Bjonnes AC, et al. Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology. Diabetes. 2016 Jun;65(6):1741–1751.
   PubMed Web of Science ®Google Scholar
• Tuomi T, Nagorny CLF, Singh P, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016 Jun 14;23(6):1067–1077.
   PubMed Web of Science ®Google Scholar
• Cappuccio FP, D’Elia L, Strazzullo P, et al. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010 Feb;33(2):414–420.
   PubMed Web of Science ®Google Scholar
• Nicolaides NC, Charmandari E, Kino T, et al. Stress-related and circadian secretion and target tissue actions of glucocorticoids: impact on health. Front Endocrinol (Lausanne). 2017;8:70.
   PubMed Web of Science ®Google Scholar
• Nicolaides NC, Charmandari E, Chrousos GP, et al. Circadian endocrine rhythms: the hypothalamic–pituitary–adrenal axis and its actions. Ann N Y Acad Sci. 2014;1318:71.
   PubMed Web of Science ®Google Scholar
• Charmandari E, Chrousos GP, Lambrou GI, et al. Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PloS One. 2011;6(9):e25612.
   PubMed Web of Science ®Google Scholar
• Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2015 Nov;154:94–103.
   PubMed Web of Science ®Google Scholar
• Ayonrinde OT, Olynyk JK, Beilin LJ, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology. 2011 Mar;53(3):800–809.
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999 Apr 2;257(1):79–83.
   PubMed Web of Science ®Google Scholar
• Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004 Jul;40(1):46–54.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011 Mar;60(3):313–326.
   PubMed Web of Science ®Google Scholar
• Ando H, Yanagihara H, Hayashi Y, et al. Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue. Endocrinology. 2005 Dec;146(12):5631–5636.
   PubMed Web of Science ®Google Scholar
• Scheer FA, Chan JL, Fargnoli J, et al. Day/night variations of high-molecular-weight adiponectin and lipocalin-2 in healthy men studied under fed and fasted conditions. Diabetologia. 2010 Nov;53(11):2401–2405.
   PubMed Web of Science ®Google Scholar
• Hoffman EL, VonWald T, Hansen K. The metabolic syndrome. South Dakota Med. 2015; Spec No:24-8.
   Google Scholar
• Aller R, Izaola O, Ruiz-Rebollo L, et al. Predictive factors of non-alcoholic steatohepatitis: relationship with metabolic syndrome. Nutricion Hospitalaria. 2015 Jun 1;31(6):2496–2502.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011 Mar;53(3):810–820.
   PubMed Web of Science ®Google Scholar
• McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol. 2006 Apr;17(2):170–175.
   PubMed Web of Science ®Google Scholar
• Mitchell M, Armstrong DT, Robker RL, et al. Adipokines: implications for female fertility and obesity. Reproduction. 2005 Nov;130(5):583–597.
   PubMed Web of Science ®Google Scholar
• Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011;22(7):259–265.
   PubMed Web of Science ®Google Scholar
• Orlik B, Handzlik G, Olszanecka-Glinianowicz M. The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease. Postepy higieny i medycyny doswiadczalnej (Online). 2010 May 7;64:212–219.
   Web of Science ®Google Scholar
• Shen C, Zhao CY, Wang W, et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol. 2014 Feb 23;14:39.
   PubMed Web of Science ®Google Scholar
• Rajala MW, Qi Y, Patel HR, et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes. 2004 Jul;53(7):1671–1679.
   PubMed Web of Science ®Google Scholar
• Qatanani M, Szwergold NR, Greaves DR, et al. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest. 2009 Mar;119(3):531–539.
   PubMed Web of Science ®Google Scholar
• Heidemann C, Sun Q, van Dam RM, et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med. 2008 Sep 2;149(5):307–316.
   PubMed Web of Science ®Google Scholar
• Gierej P, Gierej B, Kalinowski P, et al. Expression of resistin in the liver of patients with non-alcoholic fatty liver disease. Pol J Pathol. 2017;68(3):225–233.
   PubMed Web of Science ®Google Scholar
• Huang X, Yang Z. Resistin’s, obesity and insulin resistance: the continuing disconnect between rodents and humans. J Endocrinol Invest. 2016 Jun;39(6):607–615.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Polymerou V, et al. Vaspin, resistin, retinol-binding protein-4, interleukin-1alpha and interleukin-6 in patients with nonalcoholic fatty liver disease. Ann Hepatol. 2016 Sep-Oct;15(5):705–714.
   PubMed Web of Science ®Google Scholar